chlorpheniramine polistirex; codeine polistirex
TUZISTRA XR (chlorpheniramine polistirex; codeine polistirex) is mu-opioid receptor, although it can interact with other opioid receptors at higher doses. First approved in 2015.
Drug data last refreshed 8h ago · AI intelligence enriched 2d ago
TUZISTRA XR is an extended-release oral suspension combining chlorpheniramine polistirex (antihistamine) and codeine polistirex (opioid cough suppressant) for symptomatic relief of cough and related upper respiratory symptoms. Codeine acts centrally on the cough center via mu-opioid receptors, while chlorpheniramine blocks histamine-mediated inflammation and edema of respiratory mucosa. The polistirex formulation enables sustained-release delivery for extended therapeutic coverage.
Product approaching loss of exclusivity with limited linked job openings, signaling potential team consolidation and shift to generic or line extension strategies.
mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act centrally on the cough center. In excessive doses, hydrocodone will depress respiration.…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOE in ~3 years — strategic planning for patent cliff underway
Working on TUZISTRA XR in 2025 positions you at the tail end of a branded product lifecycle, offering limited growth opportunities but valuable experience in LOE management, market defense, and potential generic transition strategy. Career impact depends on employer's commitment to line extensions, authorized generics, or portfolio rotation.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo